Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Merck : and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Diseases

share with twitter share with LinkedIn share with facebook
share via e-mail
08/09/2017 | 02:10pm CEST

DARMSTADT, Germany, Aug. 8 -- Merck Millipore, a provider of solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies, issued the following news release:

Merck, a leading science and technology company, today announced that it has formed a strategic alliance with Baylor College of Medicine (Texas, U.S.) and its vaccine product development partnership (PDP), Texas Children's Hospital Center for Vaccine Development (Texas Children's CVD), to advance vaccine research and development for neglected and emerging infections.

The collaboration focuses on bringing vaccines through development to efficiently deliver them to societies in need. Merck's experts in process development and formulation are working with Texas Children's CVD scientists at Baylor to optimize the vaccine manufacturing process to increase vaccine stability and yield. Initially, these activities are targeting schistosomiasis, a deadly parasitic disease that affects millions of people a year in tropical and subtropical regions.

"Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "The alliance with Baylor College of Medicine, one of the premier research institutions in the world, is the ideal partnership to advance vaccine development and manufacturing. Together, we will support the fight against infectious diseases."

The collaboration includes training and exchange of technical know-how in process development and formulation, filling knowledge gaps that exist from research and development to manufacturing, with a focus on neglected and emerging diseases. Dr. Peter Hotez, founding Dean of the National School of Tropical Medicine at Baylor College of Medicine and co-director of the PDP, recently presented on the topic at an Access to Medicine event earlier this year in Darmstadt, Germany.

"We are excited to partner with Merck in order to advance this important vaccine. Today, schistosomiasis is considered one of the world's most devastating neglected tropical diseases, affecting hundreds of millions of the world's poorest people. We are excited about our new collaboration with Merck to advance this lifesaving vaccine," said Dr. Hotez.

Dr. Maria-Elena Bottazzi, Deputy Director of Texas Children's Hospital Center for Vaccine Development, said, "The scientific knowledge exchange from this partnership will catalyze and accelerate the product development of much-needed vaccines against the diseases of poverty. It will serve as a framework for capacity building and will establish self-reliance in vaccine development and manufacturing around the globe."

This collaboration, together with Merck's recently announced public-private partnership with the Australian Institute of Tropical Health and Medicine (James Cook University, Queensland), the Australian Government's investment promotion agency, and Baylor College of Medicine, furthers both parties' commitment to advancing research in neglected diseases globally.

About Baylor College of Medicine

Baylor College of Medicine (www.bcm.edu) in Houston is recognized as a premier academic health sciences center and is known for excellence in education, research and patient care. It is the only private medical school in the greater southwest and is ranked 21st among medical schools for research and 8th for primary care by U.S. News & World Report. Baylor is listed 19th among all U.S. medical schools for National Institutes of Health funding and number one in Texas. Located in the Texas Medical Center, Baylor has affiliations with seven teaching hospitals and jointly owns and operates Baylor St. Luke's Medical Center, part of CHI St. Luke's Health. Currently, Baylor trains more than 3,000 medical, graduate, nurse anesthesia, physician assistant and orthotics students, as well as residents and post-doctoral fellows.

In 2011, Baylor launched the National School of Tropical Medicine, which together with Texas Children's Hospital Center for Vaccine Development is leading an innovative product development partnership model for the research & development of new vaccines to combat the world's neglected tropical diseases.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
08/09 MERCK : and Baylor College of Medicine Advance Vaccine Development and Manufactu..
08/08 MERCK : NICE Recommends Erbitux® in Combination with Platinum-Based Chemotherapy..
08/07 MERCK : Presolicitation - National Centers for Environmental Health - Sigma Aldr..
08/07 MERCK : Presolicitation Notice - National Centers for Environmental Health - Sig..
08/03 DEUTSCHE BANK : Appointed Depositary Bank for Sponsored Level I American Deposit..
08/03 NANTKWEST : Announces Publication of Preclinical Data of haNK Cell Therapy in Co..
08/03 MERCK : European Patent Office to Grant Merck KGaA, Darmstadt, Germany’s P..
08/03 Q2 2017 : Merck KGaA, Darmstadt, Germany, Sets Course for Future Growth
07/31DJMERCK : 2Q 2017 -- Forecast
More news
News from SeekingAlpha
08/17 House Dems look into MS med prices, seven drug makers contacted
08/06 Merck KGaA's (MKGAF) CEO Stefan Oschmann on Q2 2017 Results - Earnings Call T..
08/03 Merck KGaA reports Q2 results
07/06 GE and others accused of breaching EU antitrust rules
07/06 Charges over misleading merger info
Financials (€)
Sales 2017 15 421 M
EBIT 2017 3 245 M
Net income 2017 1 763 M
Debt 2017 9 768 M
Yield 2017 1,36%
P/E ratio 2017 22,28
P/E ratio 2018 19,46
EV / Sales 2017 1,41x
EV / Sales 2018 1,25x
Capitalization 11 989 M
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 109 €
Spread / Average Target 17%
EPS Revisions
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-6.44%14 069
ABBVIE11.55%111 348